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Abstract
A matched case–control study was conducted to determine the
risk factors for development of candidaemia in patients requiring
intensive-care unit (ICU) treatment for more than 48 h. Patients
were matched according to length of ICU stay, age, department
of admission, year of admission and sex. Forty-ﬁve patients with
candidaemia were identiﬁed (0.6 cases/1000 patient-days). Candi-
daemia developed mainly in critically ill patients with multiple
organ failure and end-stage disease. Candida colonization and
gastrointestinal surgery were independently associated with can-
didaemia. ICU and total in-hospital mortality were 40% and
66.7%, respectively. Candidaemia-related mortality was 20%.
Candidaemia treatment failure was the only variable associated
with in-hospital mortality (p 0.008).
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Candida spp. are causing increasing numbers of opportunistic
infections in certain patient populations, including patients in
burn-trauma intensive-care units (ICUs), patients who have
undergone abdominal surgery or solid organ, bone marrow
transplantation, and patients with haematological malignancies
[1–4]. Candidiasis is associated with increased overall and
attributable mortality and morbidity, longer duration of ICU
stay, and increased costs [5,6]. Physicians often make the
diagnosis of Candida infection on the basis of symptoms and
signs of an infection and the presence of risk factors [7,8].
The aim of this study was to identify the risk factors that are
associated with the development and outcome of candida-
emia in the ICU setting.
In this retrospective case–control study, data from
patients admitted to the medical–surgical ICU of the Henry
Dunant Hospital, Athens, Greece, from January 2001 to June
2007, were recorded. Approval from the institutional review
board of the hospital was obtained. All patients who devel-
oped candidaemia 48 h or more after ICU admission were
recorded and matched with an appropriate control in a step-
wise manner for ﬁve variables: duration of ICU stay until the
development of candidaemia (±1 day), age (±5 years), depart-
ment of hospital admission (ICU, internal medicine or surgi-
cal), year of admission and sex.
Identiﬁcation of the microorganisms to the species level
was performed with the automated system Vitek 2 (Bio-
me´rieux, Durham, NC). Colonization with Candida spp. was
deﬁned as the isolation of fungi in various body sites or ﬂuid
samples (stool, urine, bronchoalveolar lavage) that was not
associated with symptoms/signs of infection. Routine exami-
nation for Candida colonization was not performed.
Data were analysed with SPSS 15.0 software (SPSS Inc,
Chicago, IL, USA). When the distribution of variables was
normal, the Mann–Whitney U-test was used for dichotomous
variables, or the t-test for continuous variables; otherwise,
the McNemar test or the Wilcoxon signed rank test, respec-
tively, was used. A two-tailed p-value of <0.05 was consid-
ered to denote statistical signiﬁcance.
Forty-ﬁve patients with candidaemia were recorded at an
incidence of 0.6 cases/1000 patient-days. In 35 of these
patients, the Candida spp. were isolated at least 48 h after
the admission to the ICU. Forty-six Candida spp. isolates
were identiﬁed. Candida albicans was the commonest isolate
(31/46, 67.4%), followed by Candida tropicalis (5/46). Nine of
these patients had concomitant multiple organ failure, and
eight had an end-stage disease; all of these patients died.
Candida colonization (p <0.01), surgery in the gastrointes-
tinal tract (GIT, p 0.01), total parenteral nutrition (p 0.02),
absolute lymphocyte count <1000/lL on the day of the posi-
tive blood culture (p 0.02), diabetes mellitus (p 0.02) and
duration of mechanical ventilation (p 0.05) were associated
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with increased risk for development of candidaemia in the bi-
variable analysis (Table 1).
In the multivariable analysis, Candida colonization
(p <0.001) and GIT surgery (p 0.025) were associated with
development of candidaemia.
Candidaemia resolved in 23 patients; ten of these patients
died. Treatment for candidaemia failed in 12 patients; all of
these patients died. In eight additional patients, the outcome
of candidaemia could not be estimated, as these patients died
before the end of treatment. Finally, two patients were trans-
ferred to another hospital. Treatment with speciﬁc antifungal
agents (ﬂuconazole, voriconazole, amphotericin B and caspo-
fungin) was not associated with the outcome of candidaemia.
Thirty of the 45 patients with candidaemia enrolled in the
study died (66.7%); the respective ICU mortality rate was
40%. The mortality rate was higher in patients with candida-
emia (those with positive blood culture after 48 h in the
ICU) than in the control group (77.1% vs. 48.6%, p 0.02).
TABLE 1. Characteristics of the
study population and outcomes
Patients with
candidaemia (N = 35)
n/N (%) or mean ± SD
Control patients
N = 35 n/N (%) or
mean ± SD p-Value
Demographics
Age (years) 70.5 ± 16.4 68.8 ± 17.8 0.57
Sex (male) 19/35 (54.3) 20/35 (57.1) 1
Duration of ICU staya (days) 33.5 ± 24.2 15.2 ± 17.3 <0.001
Comorbidity
CVD 26/35 (74.3) 25/35 (71.4) 1
Cancer 11/35 (31.4) 4/34 (11.8) 0.09
Pulmonary disease 13/35 (37.1) 13/35 (37.1) 1
Diabetes 18/35 (51.4) 7/35 (20.0) 0.02
Renal disease 13/35 (37.1) 11/33 (33.3) 1
Liver disease 2/35 (5.7) 2/35 (5.7) 1
Haematological disease 3/33 (9.1) 2/34 (5.9) 1
Neurological disease 7/35 (20.0) 9/35 (25.7) 0.75
Risk factors for candidaemia
APACHE II score at ICU admissionb 20.3 ± 7.9 20.4 ± 7.2 0.93
ARF at ICU admission 3/34 (8.8) 6/33 (18.2) 0.51
CRF at ICU admission 10/34 (29.4) 5/33 (15.2) 0.39
Blood transfusions 26/35 (74.3) 29/35 (82.9) 0.58
FFP transfusions 10.4 ± 12.4 8.6 ± 11.9 0.57
Antibiotic prophylaxis before surgery 8/30 (26.7) 5/34 (14.7) 0.75
Use of broad-spectrum antibiotics 35/35 (100) 35/35 (100) NA
Use of two or more antibiotics 35/35 (100) 35/35 (100) NA
Fever or hypothermia 31/33 (93.9) 30/34 (88.2) 0.69
WBC count >10 000/lL or
<4000/lL in candidaemia
21/32 (65.6) 18/34 (52.9) 0.39
LC <1000/lL in candidaemia 23/32 (71.9) 12/34 (35.3) 0.02
Creatinine >2 mg/dL in candidaemia 13/33 (39.4) 10/34 (29.4) 0.61
Use of steroids 13/33 (39.4) 8/35 (22.9) 0.15
Haemoﬁltration 8/35 (22.9) 4/34 (11.8) 0.34
Use of CVC 34/35 (97.1) 33/35 (94.3) 1
Use of CVC >3 days 29/32 (90.6) 32/34 (94.1) 1
Use of PVC 21/34 (61.8) 29/35 (82.9) 0.14
Use of MV 30/34 (88.2) 33/35 (94.3) 0.63
Duration of MV (days) 12.8 ± 15 10.3 ± 12.4 0.05
Tracheostomy 5/28 (17.9) 11/34 (32.4) 0.38
Folley 35/35 (100) 34/35 (97.1) 1
TPN 20/35 (57.1) 9/35 (25.7) 0.02
Absence of enteral nutrition 0/35 (0) 2/35 (5.7) 0.5
GIT surgery 14/35 (40) 3/35 (8.6) 0.01
Multiple surgery or ICU treatment 13/35 (37.1) 8/35 (22.9) 0.3
Transfer from another hospital 12/35 (34.3) 14/33 (42.4) 0.73
Diarrhoea 5/29 (17.2) 8/32 (25) 0.63
Levine 31/34 (91.2) 32/35 (91.4) 1
Use of propofol 19/31 (61.3) 13/32 (40.6) 0.42
Duration of propofol use (days) 4 ± 3.1 3.5 ± 2.1 0.67
Candida colonization 23/33 (69.7) 4/35 (11.4) <0.01
Other infections 33/35 (94.3) 25/34 (73.5) 0.07
Bacteraemia 19/34 (55.9) 10/29 (34.5) 0.12
Outcomes
Use of empirical antifungal agents 14/33 (42.4) 4/35 (11.4) 0.13
Candidaemia 35/35 (100) 0 (0%) NA
Candidaemia-related mortality 6/26 (23.1) 0/35 (0) NA
In-hospital mortality 27/35 (77.1) 17/35 (48.6) 0.02
ICU, intensive-care unit; CVD, cardiovascular disease; APACHE II, Acute Physiology and Chronic Health Evaluation II;
ARF, acute renal failure; CRF, chronic renal failure; FFP, fresh frozen plasma; WBC, white blood cell count; LC, lym-
phocyte count; CVC, central venous catheter; PVC, peripheral venous catheter; MV, mechanical ventilation; TPN,
total parenteral nutrition; GIT, gastrointestinal tract; NA, not applicable; standard deviation.
aRefers to the total duration of ICU stay, but not the duration until development of candidaemia.
bFor patients with multiple ICU admissions, the APACHE II score was calculated for the admission in which candida-
emia developed.
p-Value of <0.05 was considered to denote statistical signiﬁcance.
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Mortality rates were not different among patients treated
with different antifungal agents. All patients who presented
at the ICU with end-stage disease, as well as those who
developed multiple organ failure in the ICU, died. Death was
attributed to candidaemia in nine patients (20%). As shown
in Table 2, candidaemia treatment failure was the only vari-
able associated with mortality (p 0.008).
Candidaemia was uncommon, and developed mainly in
critically ill patients with terminal disease and coexisting mul-
tiple organ failure. In the regression analysis, Candida coloni-
zation and GIT surgery were associated with candidaemia.
Prior colonization with Candida spp. appears to be of special
importance, as the colonizing and the offending fungi are
identical in 84–94% of cases [9,10], and the probability of
infection with Candida spp. in the absence of previous coloni-
zation is very low (negative predictive value 94–100%). In
contrast, the NEMIS study reported that colonization deﬁned
as Candida isolation from the urine or stool was not associ-
ated with candidaemia [11]. Several other risk factors that
were associated with candidaemia in other studies conducted
on patients receiving ICU treatment were not independently
associated with candidaemia in the present study. However,
several of these factors were present in the majority of
patients in both groups (Table 1).
The in-hospital mortality rate was statistically higher in the
group of candidaemia patients (p 0.02), and it was mainly
related to the severity of the end-stage disease, the exis-
tence of multiple organ failure, and the frequent coexistence
of ICU-acquired infections due to multidrug-resistant patho-
gens. Candidaemia treatment failure was the only variable
associated with mortality (p 0.008). Other factors associated
with mortality in patients with candidaemia in other studies
included age <65 years, ICU stay, cancer chemotherapy, neu-
tropenia (white blood cell count <3000/lL), and severe
thrombocytopenia (platelet count <20 000/lL) [12,13].
In the present study, patients were matched according to
the duration of ICU stay until the diagnosis of candidaemia.
The major limitation was that the patients in the control
group did not require further ICU treatment at that time,
unlike patients in the candidaemia group, who all required
further ICU treatment. However, the two groups were
matched according to ﬁve characteristics, which provided a
better balance between the studied populations. The alterna-
tive choice would have been to match patients according to
the total duration of ICU stay. However, this choice would
not have ensured that the clinical status of the matched
patients was similar. The present study is further limited by
the single-centre data collection and the fact that other treat-
ment options, e.g. catheter removal or use of local antifungal
agents, were not recorded consistently and their impact on
the development and outcome of candidaemia could not be
estimated [14]. Finally, the changes in risk factors over time.
In conclusion, this study suggests that colonization with
Candida spp. and GIT surgery are the independent risk fac-
tors associated with development of candidaemia in patients
requiring ICU care for at least 48 h. In addition, the mortal-
ity rate found in the candidaemia group was statistically
higher than that in the control group.
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Abstract
Among the 1233 Salmonella enterica isolates obtained in two
Spanish hospitals, ﬁve isolates (0.4%) (serovars: Virchow, four;
Livingstone, one) had the phenotype of an extended-spectrum
b-lactamase (ESBL) producer. The genetic characterization of
the ESBL of S. enterica Livingstone revealed a blaSHV-2 gene. The
blaCTX-M-10 gene in a phage-related genetic environment was
found in one S. enterica Virchow isolate, and the blaCTX-M-9 gene
within the In60 integron was found in the three remaining
Virchow isolates. These three isolates presented indistinguish-
able or closely related pulsed-ﬁeld gel electrophoresis patterns
among themselves and also as compared with the two other
blaCTX-M-9-containing isolates previously obtained from animals.
ESBL production is an emerging mechanism of resistance in
S. enterica in the two studied hospitals.
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Salmonella enterica is a zoonotic bacterium, transmitted
through the food chain, which causes gastroenteritis and
other types of infection that require, in some cases, the use
of antimicrobial agents. S. enterica isolates harbouring
extended-spectrum-b-lactamases (ESBLs) have emerged
worldwide during the last years, and ESBLs of the CTX-M
type are increasingly reported in Salmonella, as well as in
other members of the Enterobacteriaceae [1,2]. The occur-
rence of different genes encoding CTX-M enzymes within
sul1-type integron structures that facilitate their dissemina-
tion has been previously reported [3,4], although other
genetic environments have also been described for blaCTX-M
genes [5,6]. The objective of this study was to detect and
characterize the ESBLs in S. enterica isolates recovered in
two Spanish hospitals, and also to determine the genetic
environment of ESBL genes and its possible location within
integron structures.
During the period 2000–2004, a total of 1038 clinical
isolates of S. enterica were recovered from unrelated
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